148 related articles for article (PubMed ID: 16391911)
1. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias.
Morgan MA; Reuter CW
Ann Hematol; 2006 Mar; 85(3):139-63. PubMed ID: 16391911
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutic agents in acute myeloid leukemia.
Stone RM
Exp Hematol; 2007 Apr; 35(4 Suppl 1):163-6. PubMed ID: 17379102
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in myelodysplastic syndromes.
Shadduck RK; Latsko JM; Rossetti JM; Haq B; Abdulhaq H
Exp Hematol; 2007 Apr; 35(4 Suppl 1):137-43. PubMed ID: 17379099
[TBL] [Abstract][Full Text] [Related]
4. Acute myelogenous leukemia.
Shipley JL; Butera JN
Exp Hematol; 2009 Jun; 37(6):649-58. PubMed ID: 19463767
[TBL] [Abstract][Full Text] [Related]
5. Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
Cilloni D; Messa E; Messa F; Carturan S; Defilippi I; Arruga F; Rosso V; Catalano R; Bracco E; Nicoli P; Saglio G
Ann N Y Acad Sci; 2006 Nov; 1089():411-23. PubMed ID: 17261784
[TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
Braun T; Fenaux P
Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of signaling in myelodysplastic syndrome.
Gore SD
Best Pract Res Clin Haematol; 2004 Dec; 17(4):613-22. PubMed ID: 15494298
[TBL] [Abstract][Full Text] [Related]
8. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
Yanada M; Huang X; Garcia-Manero G; O'brien S; Ravandi F; Borthakur G; Faderl S; Issa JP; Kantarjian H; Estey E
Br J Haematol; 2007 Aug; 138(4):555-7. PubMed ID: 17593249
[No Abstract] [Full Text] [Related]
9. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies.
Gore SD
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S30-5. PubMed ID: 16341238
[TBL] [Abstract][Full Text] [Related]
10. Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).
Ravandi F; Jilani I; Estey E; Kantarjian H; Dey A; Aguilar C; Jitkaroon C; Giles F; O'Brien S; Keating M; Albitar M
Leuk Res; 2007 Jun; 31(6):791-7. PubMed ID: 17156841
[TBL] [Abstract][Full Text] [Related]
11. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
[TBL] [Abstract][Full Text] [Related]
12. Emerging treatments in acute myeloid leukaemia.
Kell J
Expert Opin Emerg Drugs; 2004 May; 9(1):55-71. PubMed ID: 15155136
[TBL] [Abstract][Full Text] [Related]
13. New agents in myelodysplastic syndromes.
Jabbour EJ; Giles FJ
Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
[TBL] [Abstract][Full Text] [Related]
14. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
Klimek VM; Fircanis S; Maslak P; Guernah I; Baum M; Wu N; Panageas K; Wright JJ; Pandolfi PP; Nimer SD
Clin Cancer Res; 2008 Feb; 14(3):826-32. PubMed ID: 18245545
[TBL] [Abstract][Full Text] [Related]
15. New agents for the treatment of acute myeloid leukemia.
Tallman MS
Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Ducastelle S; Adès L; Gardin C; Dombret H; Prébet T; Deconinck E; Rio B; Thomas X; Debotton S; Guerci A; Gratecos N; Stamatoullas A; Fegueux N; Dreyfus F; Fenaux P; Wattel E
Haematologica; 2006 Mar; 91(3):373-6. PubMed ID: 16531261
[TBL] [Abstract][Full Text] [Related]
17. Current and emerging strategies for the management of acute myeloid leukemia in the elderly.
Laubach J; Rao AV
Oncologist; 2008 Oct; 13(10):1097-108. PubMed ID: 18922830
[TBL] [Abstract][Full Text] [Related]
18. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia - the biological heterogeneity.
Bruserud Ø; Reikvam H
Expert Opin Ther Targets; 2010 Nov; 14(11):1139-42. PubMed ID: 20942744
[TBL] [Abstract][Full Text] [Related]
20. Incorporating novel agents in the treatment of myelodysplastic syndromes.
Anargyrou K; Vassilakopoulos TP; Angelopoulou MK; Terpos E
Leuk Res; 2010 Jan; 34(1):6-17. PubMed ID: 19656566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]